


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously Presented) A pharmaceutical composition for preventing or treating viral infectious diseases comprising a compound represented by the following general formula (I):



wherein

A represents a phenyl group substituted with -OX, or a 3-indolyl group;

X represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms, or a linear or branched alkynyl group having 2 to 8 carbon atoms;

B represents a hydrogen atom, a hydroxyl group, an oxo group, -N(R<sup>4</sup>)(R<sup>5</sup>), =N-OH, =N-OR<sup>6</sup> or a halogen atom;

R<sup>4</sup> and R<sup>5</sup> may be the same or different, and each represent a hydrogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkenyl group having 2 to 6 carbon atoms, or a linear or branched alkynyl group having 2 to 6 carbon atoms, or R<sup>4</sup> and R<sup>5</sup> together represent a 3 to 8 membered ring;

R<sup>6</sup> represents a linear or branched alkyl group having 1 to 8 carbon atoms (which may be substituted with an amino group which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms);


D represents a hydrogen atom or a hydroxyl group; bond E represents a single bond or double bond; R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> may be the same or different, and each represent a hydrogen atom, a hydroxyl group, an amino group (which may be mono- or di-substituted with a linear

or branched alkyl group having 1 to 4 carbon atoms), -OZ, a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms; and,

Z represents a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms ;

a prodrug thereof or a pharmaceutically acceptable salt thereof.

2. **(Previously Presented)** The pharmaceutical composition according to claim 1 comprising the compound of formula (I) according to claim 1 represented by the following general formula (I'), a prodrug thereof or a pharmaceutically acceptable salt thereof:



wherein A, B, D, bond E, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are the same as defined in claim 1.

3. **(Previously presented)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof wherein A represents a phenyl group substituted with -OX at position 4, X represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms, or a linear or branched alkynyl group having 2 to 8 carbon atoms.

4. **(Previously presented)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein B represents an oxo group, a hydrogen atom, a hydroxyl group or =N-OR<sup>6</sup>.

5. **(Previously presented)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable

salt thereof, wherein  $R^1$ ,  $R^2$  and  $R^3$  may be the same or different and each represent a hydroxyl group, an amino group, or -OZ (wherein Z represents a linear or branched alkyl group having 1 to 4 carbon atoms).


6. **(Previously presented)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein A represents a phenyl group substituted with -OX at position 4, X represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms or a linear or branched alkynyl group having 2 to 8 carbon atoms, B represents an oxo group, a hydroxyl group or =N-OR<sup>6</sup>, and  $R^1$ ,  $R^2$  and  $R^3$  may be the same or different and each represent a hydroxyl group or -OZ (wherein Z represents a linear or branched alkyl group having 1 to 4 carbon atoms).

7. **(Original)** The pharmaceutical composition according to claim 6 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein X represents a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms or a linear or branched alkynyl group having 2 to 8 carbon atoms, B represents an oxo group or a hydroxyl group, and  $R^1$ ,  $R^2$  and  $R^3$  each represent a hydroxyl group.


8. **(Previously presented)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein A represents a 3-indolyl group.

9. **(Original)** The pharmaceutical composition according to claim 8 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein B represents an oxo group or a hydroxyl group, and  $R^1$ ,  $R^2$  and  $R^3$  each represent a hydroxyl group.


10. **(Currently Amended)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), a prodrug thereof of a pharmaceutically acceptable salt thereof, selected from the compounds indicated below:




No.1




No.2




No.3




No.4




No.5




No.6




No.7




No.8




No.9




No.10




No.11




No.12




No.13








No.14




No.15



21




or




11. **(Currently Amended)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, selected from the compounds indicated below:







No.1




No.2




No.3




No.5




No.6




No.7




No.8




No.9




No.12








No.14




No.15







or




12. **(Previously Presented)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, selected from the compounds indicated below:



No.1




No.6



No.7

or




No.8

13. **(Previously presented)** The pharmaceutical composition according to claim 1, wherein the viral infectious disease is HCV infection.

14. **(Original)** The pharmaceutical composition according to claim 13, wherein the HCV infection is hepatitis C.

15. **(Previously Presented)** A compound represented by the following general formula (I):



wherein

A represents a phenyl group substituted with -OX;

X represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms, or a linear or branched alkynyl group having 2 to 8 carbon atoms;

B represents a hydrogen atom, a hydroxyl group, an oxo group, -N(R<sup>4</sup>)(R<sup>5</sup>), =N-OH, =N-OR<sup>6</sup> or a halogen atom;

R<sup>4</sup> and R<sup>5</sup> may be the same or different, and each represent a hydrogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkenyl group having 2 to 6 carbon atoms, or a linear or branched alkynyl group having 2 to 6 carbon atoms, or R<sup>4</sup> and R<sup>5</sup> together represent a 3 to 8 membered ring;

R<sup>6</sup> represents a linear or branched alkyl group having 1 to 8 carbon atoms (which may be substituted with an amino group which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms ;


D represents a hydrogen atom or a hydroxyl group; bond E represents a single bond or double bond;

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> may be the same or different, and each represent a hydrogen atom, a hydroxyl group, an amino group (which may be mono- or di-substituted with a linear or

branched alkyl group having 1 to 4 carbon, atoms), -OZ, a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms; and,

Z represents a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms, with the proviso that the case in which A is a phenyl group substituted with -OX at the p position, X is a 2-isopentenyl group or a hydrogen atom, B is an oxo group, D is a hydrogen atom, E represents a double bond, and all of R<sup>1</sup> to R<sup>3</sup> are a hydroxyl group, and the case in which A is a phenyl group substituted with -OX at position p, X is a 2-isopentenyl group, B is an oxo group, D is a hydrogen atom, bond E represents a double bond, and all of R<sup>1</sup> to R<sup>3</sup> are a methoxy group are excluded) a prodrug thereof or a pharmaceutically acceptable salt thereof.

16. **(Previously Presented)** A compound represented by the following general formula (I):



wherein

A represents a phenyl group substituted with -OX;

X represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms, or a linear or branched alkynyl group having 2 to 8 carbon atoms;

B represents a hydrogen atom, a hydroxyl group, an oxo group, -N(R<sup>4</sup>)(R<sup>5</sup>), =N-OH, =N-OR<sup>6</sup> or a halogen atom;

R<sup>4</sup> and R<sup>5</sup> may be the same or different, and each represent a hydrogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkenyl group

having 2 to 6 carbon atoms, or a linear or branched alkynyl group having 2 to 6 carbon atoms, or  $R^4$  and  $R^5$  together represent a 3 to 8 membered ring;


$R^6$  represents a linear or branched alkyl group having 1 to 8 carbon atoms (which may be substituted with an amino group which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms);

D represents a hydrogen atom or a hydroxyl group; bond E represents a single bond or double bond;

$R^1$ ,  $R^2$  and  $R^3$  may be the same or different, and each represent a hydrogen atom, a hydroxyl group, an amino group (which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms), -OZ, a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms; and,

Z represents a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms, with the proviso that the case in which A is a phenyl group substituted with -OX at position p and X is a hydrogen atom, and the case in which A is a phenyl group substituted with -OX at position p, X is a 2-isopentenyl group, B is an oxo group, D is a hydrogen atom, bond E indicates a double bond, and all of  $R^1$  to  $R^3$  are a hydroxyl group or a methoxy group are excluded;  
a prodrug thereof or a pharmaceutically acceptable salt thereof.

17. **(Previously Presented)** The compound of formula (I) according to claim 15 represented by the following general formula (I'), a prodrug thereof or a pharmaceutically acceptable salt thereof:




wherein A, B, D, bond E,  $R^1$ ,  $R^2$  and  $R^3$  are the same as described in claim 15.




18. **(Previously presented)** The compound of formula (I) according to claim 15, a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein X represents a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms or a linear or branched alkynyl group having 2 to 8 carbon atoms, and B represents a hydroxyl group, an oxo group or =N-OR<sup>6</sup>.


19. **(Currently Amended)** The compound of formula (I) according to claim 15 represented by the following formulas, prodrugs thereof or a pharmaceutically acceptable salts thereof :




No.4




No.6




No.8




No.10




No.11




No.12




No.13




No.14




No.15



21




No.21




22


or




20. **(Currently Amended)** The compound of formula (I) according to claim 15 represented by the following formulas, prodrugs thereof or a pharmaceutically acceptable salts thereof :





No.6




No.8



21



or



21. **(Previously presented)** A pharmaceutical composition comprising a compound of formula (I) according to claim 15, a prodrug thereof or a pharmaceutically acceptable salt thereof.

22. **(Original)** The pharmaceutical composition according to claim 21 for preventing or treating of viral infectious diseases.

23. **(Original)** The pharmaceutical composition according to claim 22, wherein the viral infectious disease is HCV infection.

24. **(Original)** The pharmaceutical composition according to claim 23, wherein the HCV infection is hepatitis C.